Cannabinoid Cross-Tolerance Changed With the Outcome Being Measured
In one mouse study, chronic THC produced cross-tolerance to a synthetic cannabinoid’s temperature effect without the same cross-tolerance on food-maintained responding. Sharing a receptor did not make all behavioral effects interchangeable.
Two measures in the same research program
Male mice performed a task requiring repeated responses for food, and investigators also measured rectal temperature. Sensitivity to THC, CP55,940, anandamide and the benzodiazepine midazolam was assessed around a daily THC regimen.
The critical contrast
Daily THC reduced sensitivity to its own response-rate and hypothermic effects. For CP55,940, cross-tolerance appeared on hypothermia but not on response-rate suppression. Sensitivity to anandamide and midazolam was not significantly modified under the tested conditions.
Why receptor labels are insufficient
The investigators related the pattern to differences in agonist efficacy and the receptor activity required for different outcomes. Those are mechanistic interpretations, not proof that a single receptor measurement predicts every drug response. Anandamide’s rapid metabolism further complicates comparisons with directly acting experimental agonists.
A limited claim about benzodiazepines
The midazolam result is a null finding from this mouse regimen and these endpoints. It does not establish safe combined cannabis–benzodiazepine use in people. The experiment did not measure human sedation, breathing, on-road driving or a blood concentration that defines safety. A cross-tolerance opinion should identify the specific challenge drug, prior treatment and functional outcome, preserving both positive and negative comparisons.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Singh H; Schulze DR; McMahon LR. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (2011). DOI: 10.1007/s00213-010-2162-7.
